Showing results (231-240 of 679) with videos related to
Sort By:
Pageof 68
Malaria Journal|February 11, 2016
Evolution of the levels of human leukocyte antigen G (HLA-G) in Beninese infant during the first year of life in a malaria endemic area: using latent class analysisTania C d'Almeida, Ibrahim Sadissou, Gilles Cottrell, et al.Elife|August 7, 2023
Force propagation between epithelial cells depends on active coupling and mechano-structural polarizationArtur Ruppel, Dennis Wörthmüller, Vladimir Misiak, et al.Frontiers in Medicine|April 27, 2019
Interest of Pet Imaging in Multiple MyelomaBastien Jamet, Clément Bailly, Thomas Carlier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2012
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemiaIrene M Ghobrial, Philippe Moreau, Brianna Harris, et al.European Journal of Haematology|May 1, 2024
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trialMaria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myelomaHenk Lokhorst, Hermann Einsele, David Vesole, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2013
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myelomaMichel Chérel, Sébastien Gouard, Joëlle Gaschet, et al.Leukemia & Lymphoma|January 14, 2016
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myelomaPhilippe Moreau, Thierry Facon, Cyrille Touzeau, et al.Cancers|June 10, 2020
ImmunoPET in Multiple Myeloma-What? So What? Now What?Clément Bailly, Benjamin Chalopin, Sébastien Gouard, et al.European Journal of Haematology|May 1, 2020
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activationAjeeta B Dash, Jacob Zhang, Lei Shen, et al.Pageof 68